The Interleukin-17 (IL-17) Puzzle in Chagas’ Disease

dc.creatorMengel, Jose
dc.creatorCardillo, Fabíola
dc.date2018-03-20T13:11:33Z
dc.date2018-03-20T13:11:33Z
dc.date2017
dc.date.accessioned2023-09-27T00:00:30Z
dc.date.available2023-09-27T00:00:30Z
dc.identifierMENGEL, J.; CARDILLO, F. The Interleukin-17 (IL-17) Puzzle in Chagas’ Disease. Cellular Immunology and Serum Biology, v. 3, n. 2, p. 120-121, 2017.
dc.identifier2471-5891
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/25414
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8896478
dc.descriptionIn this article, we discuss an alternative explanation for the fact that the production and plasma levels of IL-17 are diminished in patients chronically infected with Trypanosoma cruzi, suffering from congestive heart failure. This alternate hypothesis considers the inhibitory pharmacological action of digoxin, a drug commonly used to treat heart failure. We believe this is a significant point to be further studied as IL-17 was initially considered to be heart-protective. Therefore, our argument has profound therapeutic implications
dc.formatapplication/pdf
dc.languageeng
dc.publisherOmmega Publishers
dc.rightsopen access
dc.subjectDoença de Chagas
dc.subjectTrypanosoma cruzi
dc.subjectInsuficiência cardíaca
dc.subjectHumanos
dc.subjectInfecção
dc.subjectChagas disease
dc.subjectTrypanosoma cruzi
dc.subjectCardiac insufficiency
dc.subjectHumans
dc.subjectInfection
dc.titleThe Interleukin-17 (IL-17) Puzzle in Chagas’ Disease
dc.typeArticle


Este ítem pertenece a la siguiente institución